Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

Meetings

Virtual Education Program

  • Presentations from the EHA2022 Congress

    Watch here

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

    Watch here

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

    Watch here

  • COLT Meeting 2019: CML related topics

    Watch here

  • COLT Meeting 2019: The CML frontier

    Watch here

    EHA 2018: Does IFN-alpha improve outcome of CML in the TKI era? (Franck E. Nicolini)

    Presentations from the 23rd Congress of EHA 

     
    EHA 2018 Nicolini


    Does IFN-α improve outcome of CML in the TKI era?
    Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

    • LSC persistence on TKI
    • IFN-α anti-tumorigenic activities
    • IFN-α alone and CML: last clinical data
    • What do we know nowadays about the combination of IFN-α and TKI?
    • IFN-α alone as maintenance therapy?
    • Conclusions
     We are very grateful for the support of Brandcast media to produce these webstreams.